Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 + AK117 versus pembrolizumab as first-line treatment for PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
CTR20243432Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab, ligufalimab, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Akeso, Inc.. Started Oct 2024; status: active.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20243432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243432.